Labcorp price target raised to $305 from $300 at Evercore ISI

Evercore ISI raised the firm’s price target on Labcorp (LH) to $305 from $300 and keeps an Outperform rating on the shares. The firm’s survey work points to a positive outlook for preclinical CROs, with rising budgets and declining cancellations, along with suggesting stable demand for discovery and toxicology services into 2025 and 2026, the analyst tells investors in a note on the group.

Elevate Your Investing Strategy:

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on LH:

Disclaimer & DisclosureReport an Issue

Labcorp price target raised to $290 from $275 at Barclays Labcorp partners with Roche to advance digital pathology capabilities Labcorp Holdings to Release Q3 2025 Financial Results Labcorp Holdings to Join Morgan Stanley Healthcare Conference Labcorp price target raised to $311 from $302 at Baird

View Comments